Phospho-PLD2 (Tyr169) Antibody

What is Phospho-PLD2 (Tyr169) Antibody and what does it detect?

Phospho-PLD2 (Tyr169) Antibody is a rabbit polyclonal antibody specifically designed to detect Phospholipase D2 (PLD2) only when phosphorylated at tyrosine residue 169. The antibody recognizes the phosphorylated epitope sequence around Tyr169 (E-N-Y(p)-L-N) derived from human PLD2 . These antibodies are typically produced by immunizing rabbits with synthetic phosphopeptides conjugated to carrier proteins like KLH, followed by affinity purification using epitope-specific phosphopeptides . The purification process often includes removing non-phospho-specific antibodies through chromatography with non-phosphopeptides, ensuring high specificity for the phosphorylated form of PLD2 . This specificity makes the antibody valuable for studying phosphorylation-dependent regulation of PLD2 activity in various cellular contexts.

The antibody detects endogenous levels of PLD2 specifically when phosphorylated at Tyr169, allowing researchers to distinguish between the phosphorylated and non-phosphorylated states of the protein . PLD2 is also known by several alternative names, including PLD 2, PLD1C, and choline phosphatase 2, with a molecular weight of approximately 95-106 kDa . The enzyme PLD2 (Uniprot ID: O14939; Gene ID: 5338) is ubiquitously expressed and plays important roles in various cellular processes through its phospholipase activity . Detection of its phosphorylation status can provide valuable insights into its regulation and function in different physiological and pathological conditions.

What are the recommended applications for Phospho-PLD2 (Tyr169) Antibody?

Phospho-PLD2 (Tyr169) Antibody is versatile and can be utilized across multiple research applications, with specific optimization requirements for each technique. For Western blot (WB) applications, the recommended dilution ranges from 1:500 to 1:3000, allowing for detection of phosphorylated PLD2 in cell or tissue lysates . When performing immunohistochemistry (IHC) on paraffin-embedded tissues (IHC-P), the optimal dilution range is typically 1:50 to 1:300, enabling visualization of phosphorylated PLD2 within the cellular context and tissue architecture . For immunofluorescence (IF) applications with paraffin-embedded samples (IF-P), similar dilution ranges to IHC are generally effective, though specific optimization may be required depending on the sample type and detection system used .

ELISA applications typically require much higher dilutions, with recommendations of approximately 1:10000, reflecting the high sensitivity of this technique . It's important to note that these dilution ranges are guidelines, and the optimal concentration should be determined empirically by each researcher for their specific experimental system and conditions . The antibody has demonstrated reliability in detecting activated PLD2 in various experimental settings, including TNF-treated Jurkat cells as shown in western blot analyses and in human brain tissues through immunohistochemistry . The specificity of the signal can be confirmed by blocking with the phospho-peptide, which should eliminate the specific signal if the antibody is truly detecting the phosphorylated form of PLD2 .

What species reactivity does Phospho-PLD2 (Tyr169) Antibody demonstrate?

The Phospho-PLD2 (Tyr169) Antibody exhibits cross-reactivity across multiple mammalian species, making it valuable for comparative studies. According to technical specifications, the antibody consistently demonstrates reactivity with human, mouse, and rat samples . This multi-species reactivity is likely due to the high conservation of the sequence surrounding the Tyr169 phosphorylation site across these mammalian species. The ability to detect phosphorylated PLD2 across different species is particularly advantageous for researchers conducting translational studies or using various animal models to investigate PLD2 function and regulation in physiological and pathological conditions.

While the primary reactivity is confirmed for human, mouse, and rat, researchers working with other species should conduct preliminary validation experiments to determine cross-reactivity with their specific samples . The antibody's reactivity profile allows for consistent experimental approaches across different model systems, facilitating comparative analyses between in vitro human cell studies and in vivo animal models. This conservation of the phosphorylation site suggests the potential biological importance of this modification across species. For human samples specifically, the antibody targets the product of gene ID 5338, corresponding to Uniprot ID O14939 (PLD2_HUMAN), which encodes the full-length phospholipase D2 protein .

How should Phospho-PLD2 (Tyr169) Antibody be stored and handled for optimal performance?

Proper storage and handling of Phospho-PLD2 (Tyr169) Antibody is crucial for maintaining its specificity and activity over time. The antibody is typically supplied in a stabilizing solution containing phosphate buffered saline (PBS) with additional components such as glycerol (50%), potential protein stabilizers like BSA (0.5%), and preservatives such as sodium azide (0.02%) . This formulation helps maintain antibody integrity during storage. The manufacturer-recommended storage temperature is -20°C for up to one year from the date of receipt . This temperature effectively minimizes degradation while maintaining the antibody in a usable state.

To preserve antibody activity over extended periods, it is essential to avoid repeated freeze-thaw cycles, which can lead to protein denaturation and diminished performance . Preparing small single-use aliquots upon first thawing the antibody is a recommended practice to minimize freeze-thaw damage. When working with the antibody, it should be thawed completely and equilibrated to room temperature before opening the vial to prevent condensation, which could introduce contaminants or dilute the antibody solution. For short-term storage during experimental procedures, keeping the antibody on ice is advisable to minimize degradation. Prior to each use, the antibody solution should be gently mixed by inversion or mild vortexing to ensure homogeneity, taking care not to introduce bubbles that could lead to oxidation .

What controls should be used to validate Phospho-PLD2 (Tyr169) Antibody specificity?

Rigorous validation of Phospho-PLD2 (Tyr169) Antibody specificity is essential for generating reliable and interpretable research data. A primary validation approach involves using the immunizing phosphopeptide as a blocking control in parallel experiments . When the antibody is pre-incubated with the phosphopeptide used for immunization, the specific signal should be significantly reduced or eliminated in Western blot, immunohistochemistry, or immunofluorescence applications, as demonstrated in analyses of TNF-treated Jurkat cells and human brain tissues . This blocking experiment confirms that the antibody is specifically recognizing the phosphorylated epitope rather than binding non-specifically to other proteins.

What is the functional significance of PLD2 phosphorylation at Tyr169?

The phosphorylation of PLD2 at tyrosine 169 represents a critical post-translational modification that significantly impacts enzyme activity and downstream signaling pathways. This specific phosphorylation event occurs within the N-terminal regulatory domain of PLD2, which contains multiple phosphorylation sites that collectively modulate enzyme function . Research has indicated that Tyr169 phosphorylation enhances PLD2 catalytic activity, thereby increasing the production of phosphatidic acid (PA) and subsequently diacylglycerol (DAG), which serve as second messengers in various cellular signaling cascades . The strategic position of Tyr169 within the protein structure suggests it may induce conformational changes that relieve auto-inhibition or enhance substrate accessibility to the catalytic site.

At the molecular level, phosphorylation at Tyr169 has been implicated in facilitating protein-protein interactions between PLD2 and its effector molecules, including components of the MAPK pathway and cytoskeletal regulators . These interactions are essential for coordinating PLD2's role in processes such as cytoskeletal reorganization, vesicle trafficking, and cell migration. In pathophysiological contexts, dysregulated phosphorylation at this site has been associated with aberrant cell proliferation and survival in various cancer models, suggesting its potential role in oncogenic transformation . The reversible nature of this phosphorylation provides a mechanism for temporal regulation of PLD2 activity in response to extracellular stimuli such as growth factors, inflammatory cytokines, and hormones, allowing for dynamic modulation of cellular responses to changing environmental conditions.

What signaling pathways regulate PLD2 phosphorylation at Tyr169?

The phosphorylation of PLD2 at Tyr169 is regulated by multiple interconnected signaling pathways that respond to diverse extracellular stimuli. Receptor tyrosine kinases (RTKs), particularly those in the epidermal growth factor receptor (EGFR) family, have been implicated as major upstream regulators that can directly or indirectly promote PLD2 phosphorylation at Tyr169 . Upon activation, these receptors initiate signaling cascades involving non-receptor tyrosine kinases such as Src family kinases (SFKs), which have been demonstrated to directly phosphorylate PLD2 at Tyr169 in response to growth factor stimulation. This phosphorylation event serves as a critical regulatory node integrating multiple signaling inputs to modulate PLD2 enzymatic activity.

Inflammatory cytokine signaling, particularly through tumor necrosis factor (TNF) receptors, also contributes to PLD2 Tyr169 phosphorylation, as evidenced by experimental data showing increased phosphorylation in Jurkat cells treated with TNF (20ng/ml for 30 minutes) . This implicates PLD2 phosphorylation in immune and inflammatory responses. Additionally, integrin-mediated signaling triggered by cell-matrix interactions activates focal adhesion kinase (FAK) and related kinases that can target PLD2 for phosphorylation, connecting PLD2 activity to cell adhesion and migration processes. The phosphorylation status of Tyr169 is further regulated by protein tyrosine phosphatases (PTPs) that remove the phosphate group, allowing for dynamic control of PLD2 activity in response to changing cellular conditions or termination of stimulus responses.

How can researchers optimize Western blot protocols for detecting Phospho-PLD2 (Tyr169)?

Optimizing Western blot protocols for detecting Phospho-PLD2 (Tyr169) requires careful attention to sample preparation, electrophoresis conditions, and detection methods to ensure specific and sensitive identification of the phosphorylated protein. When preparing cell or tissue lysates, researchers should use phosphatase inhibitors (such as sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in addition to standard protease inhibitors to preserve the phosphorylation status of PLD2 . Lysis buffers containing 1% NP-40 or RIPA buffer supplemented with 1% SDS are often effective for solubilizing membrane-associated proteins like PLD2 while maintaining phosphoepitope integrity. Sample preparation should be performed at 4°C to minimize phosphatase activity, and samples should be processed quickly to avoid degradation.

For electrophoresis, using lower percentage (7-8%) SDS-PAGE gels is recommended to achieve better resolution of high molecular weight proteins like PLD2 (approximately 95-106 kDa) . Transfer conditions should be optimized for large proteins, potentially using lower current over longer periods or semi-dry transfer systems with specialized buffers. The recommended antibody dilution ranges from 1:500 to 1:2000 for Western blot applications, but this should be empirically determined for each experimental system . Blocking with 5% BSA in TBST is generally preferred over milk for phospho-specific antibodies, as milk contains casein phosphoproteins that may interfere with detection. Including positive controls (such as TNF-treated Jurkat cells) and negative controls (such as samples with blocking phosphopeptide) in each experiment is crucial for validating specificity . Enhanced chemiluminescence (ECL) detection systems with longer exposure times may be necessary for visualizing potentially low abundance phospho-proteins, and quantification should be normalized to total PLD2 levels using a separate antibody that recognizes PLD2 regardless of phosphorylation status.

What are the considerations for immunohistochemistry and immunofluorescence with Phospho-PLD2 (Tyr169) Antibody?

Successful immunohistochemistry (IHC) and immunofluorescence (IF) applications with Phospho-PLD2 (Tyr169) Antibody require careful optimization of tissue preparation, antigen retrieval, and detection parameters. When working with formalin-fixed, paraffin-embedded (FFPE) tissues, proper fixation is critical as overfixation can mask phosphoepitopes while underfixation may lead to poor tissue morphology . Recommended fixation times typically range from 12-24 hours in 10% neutral buffered formalin. Antigen retrieval is particularly important for phospho-specific antibodies, with heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) often yielding optimal results for exposing the phosphorylated Tyr169 epitope that may be masked during fixation processes.

The optimal antibody dilution for IHC applications ranges from 1:50 to 1:300, though this should be determined empirically for each tissue type and experimental condition . Inclusion of a phosphatase inhibitor (such as sodium orthovanadate) in the antibody diluent can help maintain phosphoepitope integrity during the staining procedure. For IHC, a polymer-based detection system often provides better sensitivity than avidin-biotin complex (ABC) methods for phospho-specific antibodies. For immunofluorescence, appropriate selection of secondary antibodies with minimal background in the tissue of interest is essential, and tyramide signal amplification can be considered for detecting low-abundance phospho-proteins. Counterstaining with DAPI for nuclear visualization in IF or hematoxylin for IHC should be optimized to not obscure the specific staining pattern of phosphorylated PLD2. As demonstrated in human brain tissue sections, inclusion of a parallel section stained with antibody pre-incubated with blocking phosphopeptide serves as a critical specificity control . Additionally, optimization of the blocking step using 5-10% normal serum from the same species as the secondary antibody, supplemented with 1% BSA, can help reduce background staining while preserving specific signals.

How does PLD2 Tyr169 phosphorylation status change in disease models?

The phosphorylation status of PLD2 at Tyr169 exhibits significant alterations across various disease models, providing insights into pathological mechanisms and potential therapeutic interventions. In cancer models, increased phosphorylation of PLD2 at Tyr169 has been observed in multiple tumor types, correlating with enhanced proliferative capacity and invasiveness of cancer cells . This hyperphosphorylation is often associated with aberrant activation of upstream receptor tyrosine kinases or dysregulation of phosphatase activity, leading to sustained PLD2 enzymatic activity that promotes cancer cell survival and metastasis. The resulting elevation in phosphatidic acid production contributes to activation of mTOR signaling and other pro-survival pathways, establishing PLD2 Tyr169 phosphorylation as a potential biomarker for cancer progression and therapeutic response.

In inflammatory disease models, dynamic changes in PLD2 Tyr169 phosphorylation have been documented in response to inflammatory stimuli such as TNF, as demonstrated in Jurkat cell studies . This phosphorylation event appears to regulate the production of pro-inflammatory lipid mediators and cytokine release, potentially contributing to the perpetuation of inflammatory responses in conditions such as rheumatoid arthritis and inflammatory bowel disease. In neurodegenerative disease models, alterations in PLD2 phosphorylation status have been implicated in abnormal protein aggregation and neuronal dysfunction, with immunohistochemical studies of human brain tissue revealing distinct patterns of phosphorylated PLD2 distribution in affected regions . These disease-specific patterns of PLD2 Tyr169 phosphorylation suggest potential roles in pathogenesis and highlight opportunities for developing targeted therapeutic approaches aimed at modulating PLD2 activity through intervention in the regulatory pathways controlling its phosphorylation status.

What are the recommended dilution ranges and optimization strategies for different applications?

Optimal utilization of Phospho-PLD2 (Tyr169) Antibody across different experimental techniques requires careful attention to dilution factors and application-specific optimization strategies. For Western blot applications, the recommended dilution range spans from 1:500 to 1:3000, with initial titration experiments advised to determine the optimal concentration that provides maximum specific signal with minimal background for each experimental system . When optimizing Western blot protocols, researchers should consider varying both primary and secondary antibody concentrations independently, as well as adjusting incubation times and temperatures to achieve optimal signal-to-noise ratios. For particularly challenging samples, overnight incubation at 4°C with more dilute antibody solutions often yields better results than shorter incubations at room temperature.

For immunohistochemistry (IHC) applications, the suggested dilution range is more concentrated, typically between 1:50 and 1:300 . Optimization for IHC should include systematic testing of different antigen retrieval methods (heat-induced versus enzymatic), retrieval buffer compositions (citrate, EDTA, or Tris-based), and retrieval durations to maximize epitope accessibility while preserving tissue morphology. For immunofluorescence applications, similar dilution ranges to IHC are generally applicable, but researchers should additionally optimize mounting media selection to minimize photobleaching while maintaining signal intensity. ELISA applications typically require substantially higher dilutions, with recommendations around 1:10000, reflecting the high sensitivity of this technique . For each application, optimization should include appropriate positive and negative controls to confirm specificity, and consideration of different detection systems (such as enhanced chemiluminescence versus fluorescent secondary antibodies) to achieve the desired sensitivity and dynamic range for specific experimental objectives.

What are the key technical challenges when working with Phospho-PLD2 (Tyr169) Antibody?

Researchers working with Phospho-PLD2 (Tyr169) Antibody face several technical challenges that require careful consideration and methodological adjustments. One of the primary challenges is maintaining phosphoepitope integrity throughout experimental procedures, as phosphorylation marks are susceptible to rapid loss due to endogenous phosphatase activity . This necessitates rigorous sample handling protocols, including immediate processing of fresh samples on ice, incorporation of comprehensive phosphatase inhibitor cocktails in all buffers, and minimizing the time between sample collection and analysis or fixation. Another significant challenge involves distinguishing specific phospho-PLD2 signals from potential cross-reactivity with other phosphorylated proteins, particularly other PLD family members that may share sequence homology around phosphorylation sites.

The relatively low abundance of phosphorylated forms compared to total protein presents detection sensitivity challenges, especially in tissues or cell types with naturally low PLD2 expression . This often requires signal amplification strategies or enrichment of phosphoproteins prior to analysis. Additionally, the dynamic nature of protein phosphorylation means that the timing of sample collection relative to stimulation is critical for capturing transient phosphorylation events. Researchers may need to perform detailed time-course experiments to identify optimal windows for detecting Tyr169 phosphorylation following specific stimuli such as growth factor or cytokine treatment. Fixation and permeabilization conditions for immunohistochemistry and immunofluorescence applications must be carefully optimized, as overfixation can mask phosphoepitopes while insufficient fixation may compromise tissue morphology or cellular architecture . For quantitative applications, establishing appropriate normalization strategies is essential, typically requiring parallel detection of total PLD2 levels in addition to the phosphorylated form to account for variations in protein expression between samples.

How can researchers troubleshoot common issues with Phospho-PLD2 (Tyr169) Antibody experiments?

Effective troubleshooting of experiments using Phospho-PLD2 (Tyr169) Antibody requires systematic evaluation of each experimental step and targeted interventions for specific issues. When confronting weak or absent signals in Western blot applications, researchers should first verify protein loading and transfer efficiency using total protein stains or housekeeping proteins before investigating antibody-specific issues . If transfer appears adequate, potential remedies include increasing antibody concentration, extending incubation times, implementing more sensitive detection systems, or enhancing phosphoepitope preservation through additional phosphatase inhibitors in sample preparation. High background issues can often be addressed by increasing blocking stringency (using 5% BSA instead of milk for phospho-specific antibodies), extending washing steps, or reducing secondary antibody concentration.

For immunohistochemistry or immunofluorescence applications with poor staining results, optimization of antigen retrieval conditions is often critical . Systematic testing of different retrieval buffers (citrate pH 6.0 versus EDTA pH 9.0), retrieval durations, and temperatures can dramatically improve phosphoepitope accessibility. If non-specific staining persists despite optimized blocking, pre-absorption of the antibody with non-phospho peptides while retaining reactivity with phospho-peptides can enhance specificity. When encountering inconsistent results between experiments, standardization of sample collection timing relative to stimulation is essential for capturing the potentially transient phosphorylation events at Tyr169. For quantitative applications yielding unexpected or contradictory results, verification with alternative techniques is advisable—for example, supporting Western blot findings with immunofluorescence visualization or mass spectrometry confirmation of phosphorylation status. Particularly for experimental systems where PLD2 may be present at low abundance, consideration of enrichment approaches such as immunoprecipitation prior to detection can significantly enhance sensitivity and specificity .

What experimental design considerations maximize data quality for phosphorylation studies?

Designing robust experiments for studying PLD2 Tyr169 phosphorylation requires careful planning across multiple dimensions to ensure reliable, interpretable results. Temporal considerations are paramount, as phosphorylation events are often transient and dynamic . Researchers should implement detailed time-course experiments following stimulation (such as TNF treatment) to determine the optimal timepoints for capturing peak phosphorylation levels and their subsequent decay. Including both early (minutes) and late (hours) timepoints provides comprehensive characterization of the phosphorylation kinetics. Dose-response relationships should also be systematically explored, as different concentrations of stimuli may differentially affect the magnitude and duration of PLD2 phosphorylation at Tyr169.

Normalization strategies require careful consideration, as changes in total PLD2 expression can confound phosphorylation-specific effects . Researchers should quantify both phosphorylated and total PLD2 levels, expressing results as phospho-to-total ratios to account for expression variations. For spatial characterization of phosphorylation patterns, complementary approaches such as subcellular fractionation and immunofluorescence co-localization with organelle markers provide valuable insights into the compartmentalization of phosphorylated PLD2. Implementation of orthogonal techniques (such as combining Western blot, immunofluorescence, and mass spectrometry) strengthens confidence in observations and provides comprehensive characterization of PLD2 phosphorylation dynamics in experimental systems .

How can Phospho-PLD2 (Tyr169) Antibody be used in combination with other research tools?

Integrating Phospho-PLD2 (Tyr169) Antibody with complementary research tools creates powerful experimental strategies for comprehensive characterization of PLD2 regulation and function. Combining phospho-specific detection with PLD2 activity assays allows researchers to directly correlate phosphorylation status with enzymatic function, establishing causative relationships between Tyr169 phosphorylation and alterations in phosphatidic acid production . This integration can be particularly revealing when implemented in time-course experiments following stimulation, enabling temporal correlation between phosphorylation events and subsequent changes in enzymatic activity. Pairing phospho-specific detection with site-directed mutagenesis approaches (creating Y169F phospho-deficient or Y169E phosphomimetic mutants) provides powerful tools for dissecting the specific functional consequences of phosphorylation at this site independent of other regulatory mechanisms.

Co-immunoprecipitation experiments using the Phospho-PLD2 (Tyr169) Antibody can identify interaction partners that specifically recognize or are recruited to the phosphorylated form of PLD2, revealing phosphorylation-dependent protein complexes that may mediate downstream signaling events . For spatial analyses, combining the antibody with subcellular fractionation techniques or advanced microscopy methods such as super-resolution imaging enables detailed characterization of the subcellular distribution of phosphorylated PLD2 and its dynamic relocalization following stimulation. In complex experimental systems such as tissue samples or heterogeneous cell populations, coupling immunohistochemistry with laser capture microdissection allows isolation and molecular analysis of specific cell types exhibiting PLD2 phosphorylation.

For in vivo applications, combining the antibody with pharmacological interventions targeting upstream kinases or phosphatases provides opportunities to manipulate PLD2 phosphorylation status and observe consequent phenotypic effects. Integration with phosphoproteomics approaches offers broader contextual understanding by placing PLD2 Tyr169 phosphorylation within the larger landscape of phosphorylation-dependent signaling networks altered in response to specific stimuli or in disease states. This multi-modal approach leveraging the specificities of the Phospho-PLD2 (Tyr169) Antibody alongside complementary techniques enables researchers to construct comprehensive models of PLD2 regulation and function across diverse experimental systems and physiological or pathological contexts .